This compound is a long-acting GLP-1 analog with high receptor affinity and extended stability relative to native GLP-1, making it a common reference compound in metabolic research
1 Similarly, finding relevant and informative patient segments revealed deeper insights into patient treatment choices and how these choices reflected broader behavioral patterns and the availability of compounded versus branded GLP-1s
However, it is important to note that most clinical trials exclude patients with severe liver disease, limiting our understanding of safety in this population
Safety notes: GI side effects (oily stools, urgency) common
This was paralleled by an increase in prescriptions of GLP-1RAs among subjects on secondary prevention (that doubled from 8% in 2010 to 16% in 2018), and as fixed or flexible combination with insulin
It only took Terri one consultation to diagnose the dietary issues that were keeping me from success and provide me with a manageable plan for changing my eating habits